Policy & Regulation
Armata Pharmaceuticals names new director
11 October 2019 -

Armata Pharmaceuticals Inc (NYSE American: ARMP), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, announced yesterday that it has named Todd C Peterson, PhD as its new director.

Dr Peterson brings to the Armata board more than 35 years of experience in biotechnology and life sciences research and development across the areas of molecular biology, nucleic acids and genomics product and technology development.

Presently, Dr Peterson serves as chief scientific officer at the Allen Institute in Seattle, Washington. Prior to joining the Allen Institute in 2018, he served as chief technology officer at Synthetic Genomics Inc. Prior to joining SGI, Dr Peterson led genomics and synthetic biology R&D at Invitrogen/Life Technologies. Prior to Life Technologies, Dr Peterson held research and development positions with increasing responsibilities and scope at Genicon Sciences, Trega Biosciences, Hybritech and Gen-Probe where he focused on technology research, product development and commercialisation.